New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
18:29 EDTSMG, HALO, TRAK, SFM, HEAR, NUAN, CEMP, GSAT, GERN, MTZ, GALE, ICPT, DSTI, CALL, MMOn The Fly: After Hours Movers
UP AFTER EARNINGS: DealerTrack (TRAK), up 11.3%... DTS Inc. (DSTI), up 12.8%... Globalstar (GSAT), up 1.6%... Halozyme Therapeutics (HALO), up 2.4%. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 57.7% after announcing that 46% of OCA group met FLINT endpoint as well as reporting second quarter results... Cempra (CEMP), up 5.8% following Intercept Pharmaceuticals' FLINT announcement... Scotts Miracle-Gro (SMG), up 3.6% after board approves a $500M share repurchase authorization and announces a $2.00 per share special dividend. DOWN AFTER EARNINGS: Galena Biopharma (GALE), down 13.4%... Nuance Communications (NUAN), down 9.7%... Millennial Media (MM), down 7.1%... MasTec (MTZ), down 3.6%... Turtle Beach (HEAR), down 3.5%... magicJack (CALL), down 5.8%... Geron (GERN), down 2.4%. ALSO LOWER: Sprouts Farmers Market (SFM), down 3.7% after filing to sell 15M shares of common stock for holders.
News For TRAK;DSTI;GSAT;HALO;ICPT;CEMP;SMG;GALE;NUAN;MM;MTZ;HEAR;CALL;GERN;SFM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 17, 2015
10:07 EDTGSATHigh option volume stocks
Subscribe for More Information
10:00 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:14 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
05:53 EDTICPTIntercept initiated with a Buy, $465 target at UBS
UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.
April 16, 2015
07:10 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
April 14, 2015
07:26 EDTGALEGalena completes over-enrollment of NeuVax Phase 3 PRESENT clinical trial
Galena Biopharma announced the completion of enrollment in the NeuVax Phase 3 PRESENT, or Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment, clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting. As anticipated, Galena over-enrolled the trial by 7.7% with a total of 758 patients now in the intent-to-treat, or ITT, population. The protocol for the PRESENT trial, being conducted under an FDA approved Special Protocol Assessment, or SPA, called for 700 patients; and, the company expects this higher number of ITT patients will increase the confidence in both the timing and quality of the statistics and the final outcome of the trial. The primary endpoint is currently expected to be reached in 2018, after the last patient dosed reaches her 36th month of treatment, or a total of 141 events occur, whichever comes later.
07:10 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
April 13, 2015
09:05 EDTHALOHalozyme appoints Harry Leonhardt as Chief Compliance Officer
Subscribe for More Information
08:24 EDTICPTDeutsche Bank pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
06:07 EDTICPTIntercept announces several presentations evaluating OCA
Subscribe for More Information
April 10, 2015
09:17 EDTSMGScotts Miracle-Gro should be bought on weakness, says BMO Capital
Subscribe for More Information
April 9, 2015
17:46 EDTGALEGalena receives warning letter from FDA
Galena disclosed the following in a regulatory filing: "As previously reported by Galena Biopharma in its Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 5, following an inspection of our Portland, Oregon facility in November, the U.S. Food and Drug Administration issued a Form 483 Notice of Inspectional Observations noting deficiencies pertaining to post-marketing adverse drug experience reporting and current good manufacturing practices for Abstral and Zuplenz, our only approved products. We responded to the Form 483 Notice in a letter dated December 11, 2014. In conjunction with our response to the FDA, we initiated a number of programs and corrective actions to address the FDA's observations. On April 6, we received a Warning Letter from the FDA relating to certain of the matters originally identified in the Form 483 Notice. Specifically, the Warning Letter cites deficiencies in our response letter related to the adequacy of our written procedures for the surveillance, receipt, evaluation, and reporting of post-marketing adverse drug experiences from all sources, and the failure to report each adverse drug experience not reported under 21 CFR 314.80(c)(1)(i) at quarterly intervals."
13:49 EDTHALOHalozyme management to meet with UBS
Meeting with CEO Torley to be held in London, England on April 15 hosted by UBS.
08:20 EDTICPTWedbush reiterates $493/share acquisition value for Intercept
Subscribe for More Information
April 8, 2015
10:01 EDTTRAKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:18 EDTHALOHalozyme to proceed with Phase 3 study of pancreatic cancer candidate
Subscribe for More Information
07:10 EDTTRAKDealerTrack initiated with a Neutral at BofA/Merrill
Subscribe for More Information
06:57 EDTICPTIntercept added to short-term buy list at Deutsche Bank
Subscribe for More Information
April 6, 2015
16:02 EDTTRAKDealerTrack, Digital Air Strike enter channel, product agreements
Subscribe for More Information
08:40 EDTSFMOrganic Food sector to see increased competition, says Longbow
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use